Age-Related Immune Decline Reduces CAR-T Cell Therapy Efficacy

Age-related immune decline reduces CAR-T cell therapy efficacy

As people age, their immune systems become less efficient, posing a challenge for cancer therapies that rely on harnessing immune cells.

Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure

Chimeric antigen receptor (CAR) T cell therapy is one of the most promising cancer treatments. However, different hurdles are limiting its application and efficacy. In this context, how aging influences CAR-T cell outcomes is largely unknown. Here we show that CAR-T cells generated from aged female mice present a mitochondrial dysfunction derived from nicotinamide adenine dinucleotide (NAD) depletion that leads to poor stem-like properties and l…

Aging reduces CAR-T cell effectiveness by impairing metabolism, study shows

As people age, their immune systems become less efficient, posing a challenge for cancer therapies that rely on harnessing immune cells.

Aging reduces CAR-T cell effectiveness by impairing metabolism

Discover how aging affects CAR-T cell effectiveness and the breakthrough study on restoring NAD levels for better treatment outcomes.

Roundtable Roundup: Early CAR T-cell Therapy in Multiple Myeloma

In separate live virtual events, Sarah A. Holstein, MD, PhD, and Shashank Cingam, MD, discuss options for a patient with relapsed/refractory multiple myeloma and the use of chimeric antigen receptor (CAR) T-cell therapy.

Engineering Anti-BCMA CAR T Cells to Boost Myeloma Killing

In a groundbreaking development destined to redefine therapeutic strategies for multiple myeloma, researchers have unveiled a novel engineering approach to augment the efficacy of chimeric antigen receptor (CAR) T cells targeting B-cell maturation antigen (BCMA). The study, recently published in Nature Communications, delineates how modulation of apoptosis pathways within anti-BCMA CAR T cells can significantly enhance their tumor-killing potent…